Cargando…

Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea

BACKGROUND: Inhaled indacaterol (Onbrez Breezhaler), a long-acting β(2)-agonist, is approved in over 100 countries, including South Korea, as a once-daily bronchodilator for maintenance and treatment of chronic obstructive pulmonary disease (COPD). Here, we present an interim analysis of a post-mark...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yum, Ho-Kee, Kim, Hak-Ryul, Chang, Yoon Soo, Shin, Kyeong-Cheol, Kim, Song, Oh, Yeon-Mok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Tuberculosis and Respiratory Diseases 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5256353/ https://www.ncbi.nlm.nih.gov/pubmed/28119747 http://dx.doi.org/10.4046/trd.2017.80.1.52

Ejemplares similares

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
por: Lee, Sang Haak, et al.
Publicado: (2021)

Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials
por: Park, Jinkyeong, et al.
Publicado: (2015)

Factors Associated with Indacaterol Response in Tuberculosis-Destroyed Lung with Airflow Limitation
por: Kim, Tae Hoon, et al.
Publicado: (2019)

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
por: Ribeiro, Marcos, et al.
Publicado: (2012)

Comparison of Clinical Efficacy and Safety between Indacaterol and Tiotropium in COPD: Meta-Analysis of Randomized Controlled Trials
por: Kim, Jung Soo, et al.
Publicado: (2015)

Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis
por: Chung, Vincent C. H., et al.
Publicado: (2013)

Health-related quality of life in chronic obstructive pulmonary disease patients in Korea
por: Kim, Seon-Ha, et al.
Publicado: (2014)

Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
por: Feldman, Gregory J
Publicado: (2013)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2013)

Safety of indacaterol in the treatment of patients with COPD
por: Donohue, James F, et al.
Publicado: (2011)

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease
por: Nishijima, Yu, et al.
Publicado: (2015)

Influence of Environmental Exposures on Patients with Chronic Obstructive Pulmonary Disease in Korea
por: Hong, Yoonki, et al.
Publicado: (2014)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea
por: Kim, Changhwan, et al.
Publicado: (2019)

Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2021)

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
por: Renard, Didier, et al.
Publicado: (2011)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease
por: Burgel, Pierre-Régis, et al.
Publicado: (2017)

Lung Regeneration Therapy for Chronic Obstructive Pulmonary Disease
por: Oh, Dong Kyu, et al.
Publicado: (2017)

Real-world Safety and Efficacy of Indacaterol Maleate in Patients with Chronic Obstructive Pulmonary Disease: Evidence from the Long-term Post-marketing Surveillance in Japan
por: Taniguchi, Tomoko, et al.
Publicado: (2021)

Indacaterol: a comprehensive review
por: Rossi, Andrea, et al.
Publicado: (2013)

Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study
por: Kim, Cheong-Ju, et al.
Publicado: (2017)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials
por: Han, Jiangna, et al.
Publicado: (2013)

Effects of indacaterol versus tiotropium on respiratory mechanics assessed by the forced oscillation technique in patients with chronic obstructive pulmonary disease
por: Inui, Naoki, et al.
Publicado: (2015)

Experience of Treating Critically Ill COVID-19 Patients in Daegu, South Korea
por: Shin, Kyeong-Cheol
Publicado: (2021)

Cooling effect of urban forests on the urban heat island in Seoul, South Korea
por: Hwang, ByungMook, et al.
Publicado: (2023)

Prevalence of asymptomatic bronchiectasis and associations among the health screening population in South Korea
por: Kim, Soo Han, et al.
Publicado: (2021)

Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial
por: Rhee, Chin Kook, et al.
Publicado: (2017)

Profiling of Microbial Landscape in Lung of Chronic Obstructive Pulmonary Disease Patients Using RNA Sequencing
por: Shin, Dongjin, et al.
Publicado: (2023)

Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort
por: Singh, Mukesh P
Publicado: (2013)

Effect of tiotropium inhaler use on mortality in patients with tuberculous destroyed lung: based on linkage between hospital and nationwide health insurance claims data in South Korea
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Definition of Chronic Obstructive Pulmonary Disease Exacerbation: The Essentials of the Rome Proposal
por: Oh, Yeon-Mok
Publicado: (2023)

Air pollution and mortality in patients with chronic obstructive pulmonary disease: a cohort study in South Korea
por: Kang, Suna, et al.
Publicado: (2023)

Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium
por: Pelaia, Girolamo, et al.
Publicado: (2014)

Correlation between private education costs and parental depression in South Korea
por: Oh, Byeong Cheol, et al.
Publicado: (2020)

Determinants of Nicotine Dependence in Chronic Obstructive Pulmonary Disease
por: Sim, Yun Su, et al.
Publicado: (2017)

Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial
por: Kalberg, Chris, et al.
Publicado: (2016)

The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data
por: Kim, JinHee, et al.
Publicado: (2013)

Pulmonary complications after abdominal surgery in patients with mild-to-moderate chronic obstructive pulmonary disease
por: Kim, Tae Hoon, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_buo4pu0l0m7ef9u9ts836r58ji